Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization

Shih-Ho Wang, Li-Mien Chen, Wen-Kai Yang, Jane-Dar Lee

Shih-Ho Wang, Division of General Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung 83301, Taiwan
Li-Mien Chen, Division of Hematology/Oncology, Department of Medicine, Taichung Armed Forces General Hospital, Taichung 41152, Taiwan
Li-Mien Chen, Jane-Dar Lee, Central Taiwan University of Science and Technology, Taichung 40601, Taiwan
Wen-Kai Yang, Department of Surgery, Taichung Armed Forces General Hospital, Taichung 41152, Taiwan
Wen-Kai Yang, Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan

Author contributions: Wang SH, Chen LM and Lee JD designed the research; Yang WK performed the research and analyzed the data; Lee JD wrote the paper.

Supported by A grant from Taichung Armed Forces General Hospital, Taiwan

Correspondence to: Jane-Dar Lee, MD, PhD, Department of Surgery, Taichung Armed Forces General Hospital, No. 348, Sec 2, Chungshan Rd, Taiping Dist, Taichung 41152, Taiwan. janedar@hotmail.com
Telephone: +886-4-23925948 Fax: +886-4-23920451
Received: April 14, 2011 Revised: June 10, 2011
Accepted: June 17, 2011
Published online: November 14, 2011

Abstract

AIM: To determine the apoptosis pathway in residual viable hepatocellular carcinoma (HCC) tissues following transarterial embolization (TAE).

METHODS: Ten patients with HCC who received surgical resection after TAE were enrolled in the study group, and 24 patients with HCC who received surgical resection only served as the control group. In the study group, we measured the changes in tumor size and α-fetoprotein (AFP) levels after TAE. All tissue samples were taken from the residual tumors. The expression of various apoptotic proteins was evaluated via immunoblotting procedures. The results were analyzed using a Student’s t test.

RESULTS: Tumor size and the AFP level decreased by 46.2% and 55.3% after TAE, respectively. There was no significant difference detected for the Bcl-2/Bax ratio or the cleaved caspase-9 expression levels in either group. However, extrinsic apoptotic pathway-related expression of Fas and cleaved caspase-8 expression were significantly higher in the study group than in the control group (P < 0.05). In addition, cleaved caspase-3 expression in the study group was higher (1.62-fold) than in control group (P < 0.05).

CONCLUSION: TAE is an effective palliative therapy that decreases tumor size and AFP levels via an increase in extrinsic apoptosis pathway in patients with unresectable HCC.

© 2011 Baishideng. All rights reserved.

Key words: Apoptosis; Hepatocellular carcinoma; Transarterial embolization

Peer reviewer: Samir Abboucha, PhD, Assistant Professor, Equipe Neurosciences, Pharmacologie et Environnement, Université Cadi Ayyad, Faculté des Sciences Semlalia, Avenue My Abdellah, BP 2390, Marrakech 40000, Morocco

Wang SH, Chen LM, Yang WK, Lee JD. Increased extrinsic apoptotic pathway activity in patients with hepatocellular carcinoma following transarterial embolization. World J Gastroenterol 2011; 17(42): 4675-4681 Available from: URL: http://www.wjgnet.com/1007-9327/full/v17/i42/4675.htm DOI: http://dx.doi.org/10.3748/wjg.v17.i42.4675
INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignant cancers in the world\(^1\)\(^-\)\(^3\). Generally, HCC is induced by chronic liver injury such as liver cirrhosis. The chronic injury leads to a change in the cellular properties of the liver and curtails the delivery of blood throughout the liver. Subsequently, this pathological change leads to a reduction in blood circulation throughout the liver and accompanying hypoxia. The increased cellularity associated with the highly proliferative tumor cells also induces local hypoxia inside the actual HCC\(^8\). Hypoxia can stimulate angiogenesis to support tumor growth by inducing angiogenic factors\(^3\)\(^-\)\(^4\). Many people with advanced HCC have tumors that are unresectable by the time of disease diagnosis. Transarterial embolization (TAE) appears to be as effective as transarterial chemoembolization (TACE) and plays a major role in the treatment of patients with advanced HCC\(^5\)\(^-\)\(^6\). However, the exact molecular changes and apoptotic pathway activity of cancerous tissues following embolization still needs to be elucidated.

Several studies have reported that TACE inhibits tumor angiogenesis and induces tumor cell apoptosis. Other studies have found that TACE stimulates tumor angiogenesis and increases the proliferative activity of the tumor cells due to anoxia stress-related Bel-2 overexpression\(^7\)\(^-\)\(^8\). Unfortunately, most previous papers neglected to examine the counter factor of apoptotic protein (Bax) expression in residual viable cancerous tissues following TAE in HCC patients. We examined the expression of apoptotic proteins in the specimens taken from both groups (surgical resection only and surgery after TAE) of HCC patients. To determine whether the intrinsic or extrinsic apoptotic pathways were involved, we examined the Bel-2/Bax ratio (anti-apoptosis protein/an inducer of apoptosis), cleaved caspase-9, Fas, cleaved caspase-8 and cleaved caspase-3 expression levels.

To our knowledge, this is the first report to study the apoptotic pathway in the residual viable cancerous tissues of HCC patients following TAE. A better understanding of the molecular changes and apoptotic pathways associated with HCC will aid in the development of more effective future therapies.

MATERIALS AND METHODS

Patients and tissue samples

From January 2006 to December 2009, we enrolled 10 patients (6 men and 4 women; average age, 53.6 years) with HCC as a study group. All 10 patients received TAE with 95% alcohol and Gelform due to poor liver function and relative high initial risks for operation. The study group patients then underwent hepatic resection three weeks after the TAE. During the same period, we enrolled 24 patients (16 men and 8 women; average age, 54.4 years) who only received surgical resection for HCC as a control group. All liver tumor tissues were stored at -80°C for immunoblotting (including Bel-2/Bax ratio, cleaved caspase-9, Fas, cleaved caspase-8 and cleaved caspase-3) or fixed in formalin for immunohistochemical (IHC) staining (including caspase-9, caspase-8 and cleaved caspase-3).

Simultaneously, we measured the changes in tumor size and α fetoprotein (AFP) in the study group after TAE. The specimens were removed only after written informed consent was obtained from the patients. This study was approved by the Institute Ethics Committee of Taichung Armed Forces General Hospital.

Antibodies

Nine types of primary antibodies were used in the present study: (1) Bel-2, a mouse monoclonal antibody (sc-7382, Santa Cruz, Santa Cruz, CA, United States; dilution 1:500 for immunoblotting); (2) Bax, a mouse monoclonal antibody (sc-7480, Santa Cruz; dilution 1:200 for immunoblotting); (3,4) caspase-9, two rabbit polyclonal antibodies for immunoblotting (No. 9502, Cell Signaling, Beverly, MA, United States; dilution 1:1000 and IHC staining (sc-8355, Santa Cruz; dilution 1:100); (5) Fas, a rabbit polyclonal antibody (sc-7866, Santa Cruz; dilution 1:400 for immunoblotting); (6,7) caspase-8, a mouse monoclonal antibody for immunoblotting (No. 9746, Cell Signaling; dilution 1:1500) and a goat polyclonal antibody (sc-6134, Santa Cruz; dilution 1:50 for IHC staining); (8) cleaved caspase-3, a rabbit monoclonal antibody (No. 9664, Cell Signaling; dilution 1:1000 and 1:50 for immunoblotting and IHC staining, respectively); and (9) β-actin, a mouse monoclonal antibody (No. 8226, Abcam, Cambridge, MA, United States; dilution 1:8000 for immunoblotting). The secondary antibodies used were horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (No. 0031430, Pierce, Hercules, CA, United States; dilution 1:8000 for immunoblotting (including Bcl-2/Bax ratio, cleaved caspase-9, Fas, cleaved caspase-8 and cleaved caspase-3) or fixed in formalin for immunohistochemical (IHC) staining (including caspase-9, caspase-8 and cleaved caspase-3). Simultaneously, we measured the changes in tumor size and α fetoprotein (AFP) in the study group after TAE. The specimens were removed only after written informed consent was obtained from the patients. This study was approved by the Institute Ethics Committee of Taichung Armed Forces General Hospital.

Immunoblotting

The immunoblotting method was modified from our previous studies\(^9\)\(^-\)\(^10\). In brief, aliquots containing 100 μg of sample supernatants were added to the sample buffer and heated at 95°C for 5 min. After electrophoresis and transformation, blots (polyvinylidene fluoride membranes; Millipore, Bedford, MA, United States) were preincubated in phosphate buffer saline with 0.05% Tween 20 (PBST) buffer containing 5% (wt/vol) nonfat dried milk to minimize non-specific binding. According to the manufacturer’s manual, Bel-2, Bax, cleaved caspase-9, Fas, cleaved caspase-8, cleaved caspase-3 and β-actin antibodies should bind to proteins with molecular weights of about 26, 23, 35-37, 48, 43, 17-19 and 44 kDa, respective-
RESULTS

The tumor size and AFP levels decreased by about 46.2% and 55.3%, respectively, following TAE (Table 1). The

Bcl-2/Bax ratio and cleaved caspase-9 expression levels, both indicative of the intrinsic apoptosis pathway, demonstrated no statistical differences between the groups ($P > 0.05$; Figures 1 and 2A; Table 2). However, the expression levels of Fas and cleaved caspase-8, both involved in the extrinsic apoptosis pathway, were significantly higher in the study group ($P < 0.05$; Figure 2C and D; Table 2). Cleaved caspase-3 expression in the study group was also higher than in the control group ($P < 0.05$; Figure 2B; Table 2). Representative sections from study group patients (Figure 3A-D) and control group patients (Figure 3E-H) for IHC staining (caspase-9, caspase-8 and cleaved caspase-3) supported the immunoblotting results.

These findings demonstrated that the decreased tumor size and AFP levels in HCC patients following TAE resulted from increased activity of the extrinsic apoptosis pathway.

**DISCUSSION**

HCC is one of the most common and lethal malignant tumors worldwide. The late diagnosis and advanced underlying liver cirrhosis responsible for HCC generally makes complete resection non-viable. TACE is one of the most validated treatments for unresectable HCC in patients with preserved liver function.$^{[11-13]}$. Several studies have reported that TACE inhibits tumor angiogenesis and induces tumor cell apoptosis.$^{[14]}$. Conversely, other studies indicate that TACE stimulates tumor angiogenesis and increases proliferative activity of the tumor cells due to hypoxic stress-induced Bcl-2 overexpression.$^{[7,8]}$. Hypoxia enhances proliferation, angiogenesis, metastasis, chemo-resistance and radio-resistance to suppress differentiation and apoptosis of HCC.$^{[15]}$. Therefore, combining therapies that induce and target hypoxia may be beneficial to HCC patients. TAE appears to be as effective as TACE in improving survival rates of cirrhotic HCC patients.$^{[10,12,13]}$. TAE allows local tumor response to reach 88%, and in addition, bleeding control can be increased.
from 83% to 100%\(^{[17,18]}\). However, there have been no further studies investigating the molecular changes and apoptotic pathways of residual viable HCC tissues following TAE.

Apoptosis, in multicellular organisms, plays an important role in development and tissue homeostasis\(^{[19-21]}\). The two major mechanisms of cell death are referred to as the intrinsic and extrinsic pathways. The intrinsic (or mitochondrial) pathway is induced by cellular stress, which involves Bcl-2, Bax, mitochondrial outer-membrane permeability and caspase-9 protein. The extrinsic (or death receptor) pathway is induced by specific ligands that engage death receptors, which generally involves Fas and the binding and activation of caspase-8 protein\(^{[22-24]}\). In the human apoptotic pathway cascade, 14 caspases (cysteinyl aspartate-specific proteinases) have been discovered to date\(^{[25,26]}\). Among them, caspase-3 is considered the most crucial executioner protease, as it is essential for apoptotic death in mammalian cells\(^{[27]}\).

In this study, tumor size and AFP level were decreased by 46.2% and 55.3% following TAE, respectively. There was no significant difference of Bcl-2/Bax ratio and cleaved caspase-9 expression in either group. However, the expression levels of Fas and cleaved caspase-8, both involved in the extrinsic pathway, were significantly higher in the study group than in control group. In addition, increased cleaved caspase-3 expression was also observed in the TAE group (1.62-fold over the control group level). These findings demonstrate increased apoptosis through the extrinsic pathway in HCC patients following TAE. Previous studies had not examined the expression of proliferative and apoptotic proteins (Bcl-2, Bax, Fas, caspase-8).
Figure 3  Representative sections of patients from the study (A-D) and control (E-H) groups after hematoxylin staining (negative control, A and E), caspase-9 immunostaining (B and F), caspase-8 immunostaining (C and G) or cleaved caspase-3 immunostaining (D and H). Study: HCC post-TAE; Control: HCC. Higher immunoreactivity of caspase-8 and cleaved caspase-3 stain was observed in the study group than in the control group. Magnification, 400 x. HCC: Hepatocellular carcinoma; TAE: Transarterial embolization.
and Bax) in residual viable HCC tissues simultaneously.

In conclusion, our data indicate that TAE is an effective palliative therapy that decreases tumor size and AFP levels via increasing the extrinsic apoptosis pathway in patients with unresectable HCC. Thus, it would be of interest to investigate whether increasing the expression of extrinsic apoptotic proteins could provide more effective treatment for patients with HCC.

COMMENTS

Background

Transarterial embolization (TAE) plays a major role in the treatment of patients with unresectable hepatocellular carcinoma (HCC). However, the apoptotic pathway of residual viable HCC tissues following TAE remains unclear. Elucidating the apoptosis pathway associated with residual viable HCC following a TAE procedure should aid in the development of more effective therapies in the future.

Research frontiers

To evaluate potential therapeutic effects, the authors examined the changes in tumor size and α fetoprotein (AFP) levels following TAE. There are two major mechanisms of cell death, and the intrinsic and extrinsic pathways. The intrinsic (or mitochondrial) pathway is induced by cellular stress, which involves Bcl-2, Bax, and caspase-9 protein. The extrinsic (death receptor) pathway is induced by specific ligands that engage death receptors, which involves Fas and the binding and activation of caspase-8 protein. Caspase-3 is considered as the crucial executioner protease because it is essential for apoptotic death in mammalian cells. All of these apoptotic proteins were examined during this study.

Innovations and breakthroughs

This is the first report to study the apoptotic pathway in the residual viable cancerous tissues of patients with HCC following TAE. A better understanding of the molecular changes in and apoptotic pathways of HCC should lead to the development of more efficacious therapies in the future.

Applications

TAE is an effective therapy for decreasing tumor size and AFP levels via increasing the extrinsic pathway apoptosis in patients with unresectable HCC. Thus, it would be of interest to investigate whether further increasing the expression of extrinsic apoptotic proteins could provide more effective treatment for patients with HCC.

Peer review

This is a study showing different expression of apoptotic proteins in residual viable HCC tissues in patients subjected to TAE or not. The authors demonstrated that in TAE group there is a significant increase of apoptosis through the extrinsic apoptosis pathway associated with residual viable HCC following a TAE procedure. This is the first report to study the apoptotic pathway in the residual viable hepatocellular carcinoma following TAE.

REFERENCES

1. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136: 125-135
2. Kusakabe A, Tanaka Y, Orioto E, Sugawara F, Kurbanov F, Sakamoto T, Shinaki N, Hiroshima N, Hasegawa I, Ohno T, Ueda R, Mizokami M. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007; 42: 298-305
3. Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 2002; 80: 703-714
4. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005; 42: 358-364
5. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholangitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25
6. Pleguezuelo M, Marelli L, Misseri M, Germani G, Calvaruso V, Viruochakis E, Pinelopi M, Burroughs AK. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 2008; 8: 1623-1641
7. Wang B, Xu H, Gao QZ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008; 49: 523-529
8. Kobayashi N, Ishii M, Ueno Y, Kishita N, Chida N, Iwasaki T, Toyota T. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 1999; 19: 25-31
9. Lee JD, Lee TH, Cheng WH, Jeng SY. Involved intrinsic apoptotic pathway of testicular tissues in varicocele-induced rats. World J Urol 2009; 27: 527-532
10. Lee JD, Yang WK, Lai CH. Involved intrinsic apoptotic pathway in the varicocele and varicoceal veins. Ann Vasc Surg 2010; 24: 769-774
11. Maleux G, van Malensteijn H, Vandezande V, Heye S, Vaninbroux J, Nevens F, Verslype C. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis 2009; 27: 157-163
12. Tschatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010; 37: 89-93
13. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol 2010; 17: 1234-1246
14. Lu W, Li YH, He XF, Zhao JB, Chen Y, Mei QL. Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization. Cardiovasc Intervent Radiol 2008; 31: 1133-1140
15. Wu XZ, Xie GB, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1178-1182
16. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 2010; 30: 741-749
17. Vogl TJ, Zangos S, Balzer JO, Nabil M, Rao P, Eicher K, Bechstein WO, Zeuzem S, Abdelkader A. [Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]. Rofo 2007; 179: 1113-1126
18. Vogl TJ, Naguib NN, Mour-Elidin NE, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 2009; 72: 505-516
19. Jin Z, El-Deiry WS. Overview of cell cycle signaling pathways. Cancer Biol Ther 2005; 4: 139-163
20. Marsden VS, O’Connor L, O’Reilly LA, Silke J, Metafca DK, Ekert PG, Huang DC, Coconni F, Kuida K, Tomasselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM, Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-637
21. Ducasse E, Giannakakis K, Chevalier J, Dasnoy D, Papinck P, Speziale F, Fiorani P, Faragagiana T. Dysregulated apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg 2005; 29: 316-323
22. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811
23. Arnaout D, Parone P, Martinou JC, Antonsson B, Estaquio J, Armeisen JC. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol 2002; 159.
24 Chipuk JE, Green DR. Do inducers of apoptosis trigger caspase-independent cell death? Nat Rev Mol Cell Biol 2005; 6: 268-275

25 Fox R, Aubert M. Flow cytometric detection of activated caspase-3. Methods Mol Biol 2008; 414: 47-56

26 Brunelle JK, Chandel NS. Oxygen deprivation induced cell death: an update. Apoptosis 2002; 7: 475-482

27 Said TM, Paasch U, Glander HJ, Agarwal A. Role of caspases in male infertility. Hum Reprod Update 2004; 10: 39-51

S-Editor Tian L, L-Editor Ma JY E-Editor Zhang DN